This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth and tumor blood vessel growth.

Principal Investigator:
Rubin, Elyssa

Research Coordinator:
Kathryn Duvall
(714) 509-8646

Visit clinicaltrials.gov for more information about this trial.


  • Clinical Trial Info
  • IRB Number: 170541
  • Sponsor: Children's Oncology Group
  • Protocol Number: ADVL1622
  • NCT Number: NCT02867592
  • Research Type: Adolescents and Young Adults, Recurrent/Refractory Cancer, Solid Tumors
  • Phase: I
  • Status: Active - Closed to Enrollment

Inclusion

  • ≥ 2 years and ≤ 30 years of age for all strata except ≤ 18 years for MTC, RCC, and HCC
  • Ewing Sarcoma, RMS, NRMS, ASPS, CCS, Wilms, Rare Tumors
  • Measurable disease

Exclusion

  • Previous treatment with cabozantinib or another MET/HGF inhibitor
  • Corticosteroids: if not a stable or decreasing dose
  • Anti-GVHD or agents to prevent organ rejection post-transplant
  • CYP3A4 active agents
  • Unable to swallow intact tablets
  • Uncontrolled infection